Next, we performed CD68 (macrophage marker) and CD206 (M2 macrophage marker) immunostaining to address the participation of naringenin-promoted TFEB activation and M2 polarization in the treatment of AAAs in vivo. This evidence concerns the gene TFEB and achalasia-alacrima syndrome.